HCPCS Level II code Q5154 denotes a 5 mg unit of omalizumab-igec (Omlyclo), a biosimilar formulation of omalizumab used for subcutaneous or injectable administration. Nationally, accurate coding for biosimilar biologics affects payment, prior authorization pathways, and product selection in allergy and immunology, pulmonology, and outpatient infusion settings. This code matters as biosimilar adoption expands and payers refine coverage and reimbursement policies for biologics.

Key payers covered include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of what this code represents, typical sites of service, and the clinical context for omalizumab biosimilar use. The publication also outlines what to expect in payer coverage considerations, common modifiers in use, and related service-line implications where data are available.

The report provides benchmarks and policy context relevant to coding, billing, and administration of biosimilar injectable biologics, plus practical notes on documentation and claim reporting. Data not available in the input are reported as unavailable where applicable.